Non-invAsive VentIlation for early General wArd respiraTory failurE (NAVIGATE): A multicenter randomized controlled study. Protocol and statistical analysis plan

Few randomized trials have evaluated the use of non-invasive ventilation (NIV) for early acute respiratory failure (ARF) in non-intensive care unit (ICU) wards. The aim of this study is to test the hypothesis that early NIV for mild-moderate ARF in non-ICU wards can prevent development of severe ARF...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contemporary clinical trials 2019-03, Vol.78, p.126-132
Hauptverfasser: Cabrini, Luca, Brusasco, Claudia, Roasio, Agostino, Corradi, Francesco, Nardelli, Pasquale, Filippini, Matteo, Cotticelli, Virginia, Belletti, Alessandro, Ferrera, Lorenzo, Antonucci, Elio, Baiardo Redaelli, Martina, Lattuada, Marco, Colombo, Sergio, Olper, Luigi, Ponzetta, Giuseppe, Ananiadou, Sofia, Monti, Giacomo, Severi, Luca, Maj, Giulia, Giardina, Giuseppe, Biondi-Zoccai, Giuseppe, Benedetto, Umberto, Gemma, Marco, Cavallero, Sarah Sophia Michelle, Hajjar, Ludhmila Abrahao, Zangrillo, Alberto, Bellomo, Rinaldo, Landoni, Giovanni
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Few randomized trials have evaluated the use of non-invasive ventilation (NIV) for early acute respiratory failure (ARF) in non-intensive care unit (ICU) wards. The aim of this study is to test the hypothesis that early NIV for mild-moderate ARF in non-ICU wards can prevent development of severe ARF. Pragmatic, parallel group, randomized, controlled, multicenter trial. Non-intensive care wards of tertiary centers. Non-ICU ward patients with mild to moderate ARF without an established indication for NIV. Patients will be randomized to receive or not receive NIV in addition to best available care. We will enroll 520 patients, 260 in each group. The primary endpoint of the study will be the development of severe ARF. Secondary endpoints will be 28-day mortality, length of hospital stay, safety of NIV in non-ICU environments, and a composite endpoint of all in-hospital respiratory complications. This trial will help determine whether the early use of NIV in non-ICU wards can prevent progression from mild-moderate ARF to severe ARF.
ISSN:1551-7144
1559-2030
DOI:10.1016/j.cct.2019.02.001